NCT00816400View on ClinicalTrials.gov

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

March 2, 2009

Primary Completion Date

January 19, 2012

Study Completion Date

January 19, 2012

Conditions
Cancer
Interventions
DRUG

MEDI-575

MEDI-575 as an IV infusion

Trial Locations (5)

Unknown

Research Site, Denver

Research Site, Indianapolis

Research Site, Las Vegas

Research Site, Dallas

Research Site, Norfolk

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY